Supercritical antisolvent versus coevaporation -: Preparation and characterization of solid dispersions

被引:9
作者
Majerik, Viktor
Horvath, Geza
Szokonya, Laszlo
Charbit, Gerard
Badens, Elisabeth
Bosc, Nathalie
Teillaud, Eric
机构
[1] Univ Pannonia, Dept Chem Engn Sci, H-8201 Veszprem, Hungary
[2] Univ Paul Cezanne, Lab Procedes Propres & Environm, Aix En Provence, France
[3] Merck Sante Sas, Lyon, France
关键词
solid dispersion; poorly water-soluble drug; oxeglitazar; supercritical antisolvent; coevaporation;
D O I
10.1080/03639040601150286
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The objective of this work was to improve the dissolution rate and aqueous solubility of oxeglitazar. Solid dispersions of oxeglitazar in PVP K17 ( polyvinilpyrrolidone) and poloxamer 407 ( polyoxyethylene- polyoxypropylene block copolymer) were prepared by supercritical antisolvent ( SAS) and coevaporation ( CoE) methods. Drug-carrier formulations were characterized by powder X-ray diffraction, Fourier transform infrared spectroscopy, scanning electron microscopy, gas chromatography, UV/VIS spectroscopy and in vitro dissolution tests. The highest dissolution rate ( nearly 3- fold higher than raw drug) was achieved by preparation of drug/PVP K17 coevaporate. Oxeglitazar/PVP K17 solid dispersions were stabilized by hydrogen bonding but contained higher amount of residual dichloromethane (DCM) than poloxamer 407 formulations regardless of the method of preparation. SAS prepared oxeglitazar/poloxamer 407 dissolved more than two times faster than raw drug. However, unlike PVP K17, poloxamer 407 did not form a single phase amorphous solid solution with oxeglitazar which has been manifested in higher degrees of crystallinity, too. Among the two techniques, evaluated in this work, conventional coevaporation resulted in higher amorphous content but SAS reduced residual solvent content more efficiently.
引用
收藏
页码:975 / 983
页数:9
相关论文
共 35 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]  
BADENS E, 2004, P EUR C DRUG DEL PHA, P46
[3]  
BADENS E, 2005, P 7 INT S SUP FLUIDS
[4]   Control of the physical form of salmeterol xinofoate [J].
Beach, S ;
Latham, D ;
Sidgwick, C ;
Hanna, M ;
York, P .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 1999, 3 (05) :370-376
[5]   Influence of the preparation method on residual solvents in biodegradable microspheres [J].
Bitz, C ;
Doelker, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 131 (02) :171-181
[6]   Analysis of the supersaturation and precipitation process with supercritical CO2 [J].
Bristow, S ;
Shekunov, T ;
Shekunov, BY ;
York, P .
JOURNAL OF SUPERCRITICAL FLUIDS, 2001, 21 (03) :257-271
[7]  
Cassidy O., 1998, European Journal of Pharmaceutical Sciences, V6, pS23
[8]  
CHARBIT G, 2004, SUPERCRITICAL FLUID, V138, P159
[9]  
Coates J., 2000, ENCY ANAL CHEM, P10815, DOI DOI 10.1002/9780470027318.A5606
[10]   Preparation and study of the characteristics of dithranol:polyvinylpyrrolidone coevaporates [J].
Delneuville, I ;
Dechesne, JP ;
Delattre, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 168 (01) :109-118